Detection and Prevention of Cancer-Related Cardiovascular Toxicity Registry
NCT ID: NCT06086132
Last Updated: 2025-06-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
10000 participants
OBSERVATIONAL
2025-05-01
2026-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
BreAst Cancer and Cardiotoxicity Induced by RAdioTherapy: the BACCARAT Study
NCT02605512
Characterization and Kinetic of Chemotherapy-induced Cardiovascular Toxicity in Breast Cancer
NCT05803889
Reporting, Evaluating, Preventing and Treating the Cardiotoxicity Induced by Anticancer Drugs During a Specific Cardio-oncology Consult and Follow up in Routine Care
NCT03882580
Biomarkers to Predict Cancer Therapy-related Cardiotoxicity
NCT06353191
Effect of Concomitant Radiotherapy and Trastuzumab on Cardiotoxicity of Patients Treated for Early Breast Cancer
NCT01572883
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Breast cancer
Newly diagnosed breast cancer undergoing treatment with anthracyclines analogues with or without radiotherapy, with or without trastuzumab, or other anticancer drugs.
(Non-interventional prospective patient registry)
Prospective validation of the HFA-ICOS risk score in a subset of subjects with newly diagnosed breast cancer and undergoing treatment with anthracyclines analogues with or without radiotherapy
Follow-up visits at baseline, 3-months, and 1-year
Female and Male
Diagnosis of cancer scheduled for treatment according to the treating physician's discretion.
(Non-interventional patient registry)
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Prospective validation of the HFA-ICOS risk score in a subset of subjects with newly diagnosed breast cancer and undergoing treatment with anthracyclines analogues with or without radiotherapy
Follow-up visits at baseline, 3-months, and 1-year
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Capable of giving informed consent
* Diagnosis of cancer scheduled for treatment according to treating physician's discretion
* Life expectancy \>1 year
* For the prospective validation of HFA-ICOS risk score validation: Newly diagnosed breast cancer undergoing treatment with anthracyclines analogues with or without radiotherapy, with or without trastuzumab, or other anticancer drugs
Exclusion Criteria
* Not able to give informed consent
* Life expectancy \<1 year
* Advanced-stage cancer not eligible for treatment (subjects with an indication of palliative care) according to treating physician's
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone Palermo
OTHER
University of Bologna
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Olivia Manfrini, MD
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Prof. Olivia Manfrini, MD
Role: PRINCIPAL_INVESTIGATOR
University of Bologna
Prof. Giuseppina Novo, MD
Role: PRINCIPAL_INVESTIGATOR
Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Bologna
Bologna, , Italy
Azienda Ospedaliera Universitaria Policlinico "Paolo Giaccone"
Palermo, , Italy
Ss. Cyril and Methodius University in Skopje, University Clinic
Skopje, , North Macedonia
University of Belgrade, Clinical Center of Serbia
Belgrade, , Serbia
University of Belgrade, Clinical Hospital Center Bezanijska kosa
Belgrade, , Serbia
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
References
Explore related publications, articles, or registry entries linked to this study.
Lyon AR, Lopez-Fernandez T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, Boriani G, Cardinale D, Cordoba R, Cosyns B, Cutter DJ, de Azambuja E, de Boer RA, Dent SF, Farmakis D, Gevaert SA, Gorog DA, Herrmann J, Lenihan D, Moslehi J, Moura B, Salinger SS, Stephens R, Suter TM, Szmit S, Tamargo J, Thavendiranathan P, Tocchetti CG, van der Meer P, van der Pal HJH; ESC Scientific Document Group. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022 Nov 1;43(41):4229-4361. doi: 10.1093/eurheartj/ehac244. No abstract available.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ISACS CARDIONCO-PREDICT
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.